Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) — Market Cap & Net Worth
Market Cap & Net Worth: Crinetics Pharmaceuticals Inc (CRNX)
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) has a market capitalization of $9.01 Billion ($9.01 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2408 globally and #887 in its home market, demonstrating a 0.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crinetics Pharmaceuticals Inc's stock price $84.95 by its total outstanding shares 106095205 (106.10 Million). Also see Crinetics Pharmaceuticals Inc assets under control for a full breakdown of the balance sheet.
Crinetics Pharmaceuticals Inc Market Cap History: 2018 to 2026
Crinetics Pharmaceuticals Inc's market capitalization history from 2018 to 2026. Data shows growth from $3.18 Billion to $9.01 Billion (16.52% CAGR). Also see Crinetics Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Crinetics Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.34% | #54 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.02% | #276 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.48% | #36 of 263 |
Weight: Crinetics Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Crinetics Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Crinetics Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Crinetics Pharmaceuticals Inc (CRNX) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
641.73x
Crinetics Pharmaceuticals Inc's market cap is 641.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $3.18 Billion | $2.43 Million | -$27.11 Million | 1310.46x | N/A |
| 2019 | $2.66 Billion | $1.19 Million | -$49.53 Million | 2231.29x | N/A |
| 2020 | $1.50 Billion | $71.00K | -$72.86 Million | 21084.55x | N/A |
| 2021 | $3.01 Billion | $1.08 Million | -$106.72 Million | 2796.07x | N/A |
| 2022 | $1.94 Billion | $4.74 Million | -$159.95 Million | 409.87x | N/A |
| 2023 | $3.77 Billion | $4.01 Million | -$214.53 Million | 940.66x | N/A |
| 2024 | $5.42 Billion | $1.04 Million | -$298.41 Million | 5221.03x | N/A |
| 2025 | $4.94 Billion | $7.70 Million | -$465.32 Million | 641.73x | N/A |
Competitor Companies of CRNX by Market Capitalization
Companies near Crinetics Pharmaceuticals Inc in the global market cap rankings as of September 16, 2026. Review tangible net worth ratio of Crinetics Pharmaceuticals Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Crinetics Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Crinetics Pharmaceuticals Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Crinetics Pharmaceuticals Inc's market cap moved from $3.18 Billion to $ 9.01 Billion, with a yearly change of 16.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.01 Billion | +82.49% |
| 2025 | $4.94 Billion | -8.96% |
| 2024 | $5.42 Billion | +43.70% |
| 2023 | $3.77 Billion | +94.43% |
| 2022 | $1.94 Billion | -35.59% |
| 2021 | $3.01 Billion | +101.35% |
| 2020 | $1.50 Billion | -43.76% |
| 2019 | $2.66 Billion | -16.34% |
| 2018 | $3.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Crinetics Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.01 Billion USD |
| MoneyControl | $9.01 Billion USD |
| MarketWatch | $9.01 Billion USD |
| marketcap.company | $9.01 Billion USD |
| Reuters | $9.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more